Dr Matthew Matasar speaks to ecancer about the ELM-1 study presented at ASH 2024.

The study explores bispecific antibody therapy, specifically odronextamab, for patients with diffuse large B-cell lymphoma who did not respond to CAR T-cell therapy.

He reports a 48% overall response rate and a 32% complete response rate in heavily pretreated patients.

The treatment shows a median response duration of 14.8 months and is considered safe, with manageable side effects.

Dr Matasar believes that bispecific antibody therapies are an encouraging strategy for these difficult to treat patients.